×
Evolus Net Profit Margin 2016-2025 | EOLS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Evolus net profit margin from 2016 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
Evolus Net Profit Margin 2016-2025 | EOLS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Evolus net profit margin from 2016 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$229.3B
Boston Scientific (BSX)
$152.9B
Stryker (SYK)
$146B
EssilorLuxottica (ESLOY)
$145.1B
Medtronic (MDT)
$119.2B
Lonza Group Ag (LZAGY)
$48.3B
Haleon (HLN)
$43.3B
ResMed (RMD)
$41.7B
Agilent Technologies (A)
$33.9B
GE HealthCare Technologies (GEHC)
$33.5B
Terumo (TRUMY)
$27.6B
Koninklijke Philips (PHG)
$26.5B
Insulet (PODD)
$22.6B
Zimmer Biomet Holdings (ZBH)
$20.4B
Smith & Nephew SNATS (SNN)
$15.9B
Baxter (BAX)
$12.4B
Sunny Optical Technology (SNPTF)
$10.8B
Demant (WILYY)
$8.1B
Bio-Rad Laboratories (BIO)
$7.7B
Lantheus Holdings (LNTH)
$3.7B
Shandong Weigao Medical Polymer (SHWGF)
$3.5B
Envista Holdings (NVST)
$3.4B
Prestige Consumer Healthcare (PBH)
$3.2B
Perrigo (PRGO)
$3.1B
ICU Medical (ICUI)
$3B
Haemonetics (HAE)
$2.6B
LeMaitre Vascular (LMAT)
$2.2B
Curaleaf Holdings (CURLF)
$1.8B
AtriCure (ATRC)
$1.8B
QuidelOrtho (QDEL)
$1.8B